NCT06538480View on ClinicalTrials.gov

Confirmatory Study of PRGN-2012 in Patients With RRP

PHASE3SuspendedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2029

Conditions
Recurrent Respiratory PapillomatosisPapillomavirus InfectionPapillomaviridae
Interventions
DRUG

PRGN-2012

PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.

Trial Locations (3)

20892

National Institute of Health, Bethesda

30322

Winship Cancer Institute, Emory University, Atlanta

45267

University of Cincinnati, Cincinnati

Sponsors

Lead Sponsor

Precigen, Inc
All Listed Sponsors
lead

Precigen, Inc

INDUSTRY

NCT06538480 - Confirmatory Study of PRGN-2012 in Patients With RRP | Biotech Hunter | Biotech Hunter